Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

This post was originally published on News-medical.net

You will shortly be re-directed to the publisher's website

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024.